

## **METHOCARBAMOL- methocarbamol tablet**


### **American Health Packaging**

-----  
**Methocarbamol Tablets USP**  
**8455901/0320**  
**Rx only**

### **DESCRIPTION**

Methocarbamol tablets USP a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula  $C_{11}H_{15}NO_5$ . Its molecular weight is 241.24. The structural formula is shown below.



Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and n-hexane.

Methocarbamol tablets USP are available as 500 mg and 750 mg tablets for oral administration. Methocarbamol tablets USP 500 mg and 750 mg contain the following inactive ingredients: sodium lauryl sulfate, sodium starch glycolate, povidone K 90, polyethylene glycol, magnesium stearate, colloidal silicon dioxide, low substituted hydroxypropyl cellulose and stearic acid.

### **CLINICAL PHARMACOLOGY**

The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

#### **Pharmacokinetics**

In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.

#### **Special populations**

*Elderly*

The mean ( $\pm$ SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean ( $\pm$ SD) age, 69 ( $\pm$ 4) years) was slightly prolonged compared to a younger (mean ( $\pm$ SD) age, 53.3 ( $\pm$ 8.8) years), healthy population (1.5 ( $\pm$ 0.4) hours versus 1.1 ( $\pm$ 0.27) hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively).

#### *Renally impaired*

The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean ( $\pm$ SD) elimination half-life in these two groups was similar: 1.2 ( $\pm$  0.6) versus 1.1 ( $\pm$ 0.3) hours, respectively.

#### *Hepatically impaired*

In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects. The mean ( $\pm$ SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 ( $\pm$ 1.62) hours and 1.11 ( $\pm$ 0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.

## **INDICATIONS & USAGE**

Methocarbamol tablets USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.

## **CONTRAINDICATIONS**

Methocarbamol tablets USP are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

## **WARNINGS**

Since methocarbamol may possess a general CNS depressant effect, patients receiving methocarbamol tablets USP should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of methocarbamol tablets USP has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol tablets USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (**see PRECAUTIONS, Pregnancy**).

### **Use In Activities Requiring Mental Alertness**

Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are

reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

## **PRECAUTIONS**

### **Information for Patients**

Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.

Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

### **Drug Interactions**

**See WARNINGS and PRECAUTIONS** for interaction with CNS drugs and alcohol.

Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

### **Drug/Laboratory Test Interactions**

Methocarbamol may cause a color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

### **Carcinogenesis, Mutagenesis. Impairment of Fertility**

Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.

### **Pregnancy**

#### *Teratogenic effects -Pregnancy Category C*

Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol tablets USP should be given to a pregnant woman only if clearly needed.

Safe use of methocarbamol tablets USP has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol tablets USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards ( **see WARNINGS**).

### **Nursing Mothers**

Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when

methocarbamol tablets USP are administered to a nursing woman.

## **Pediatric Use**

Safety and effectiveness of methocarbamol tablets USP in pediatric patients below the age of 16 have not been established.

## **ADVERSE REACTIONS**

Adverse reactions reported coincident with the administration of methocarbamol include:

*Body as a whole:* Anaphylactic reaction, angioneurotic edema, fever, headache

*Cardiovascular system:* Bradycardia, flushing, hypotension, syncope, thrombophlebitis

*Digestive system:* Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting

*Hemic and lymphatic system:* Leukopenia

*Immune system:* Hypersensitivity reactions

*Nervous system:* Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo

*Skin and special senses:* Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticarial

## **OVERDOSAGE**

Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.

In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.

## **Treatment**

Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

## **DOSAGE & ADMINISTRATION**

Methocarbamol Tablets USP 500 mg – Adults:

Initial dosage: 3 tablets q.i.d.

Maintenance dosage: 2 tablets q.i.d.

Methocarbamol Tablets USP 750 mg – Adults:

Initial dosage: 2 tablets q.i.d.

Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.

Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

## **HOW SUPPLIED**

Methocarbamol tablets USP 500 mg are white to off white, capsule shaped, tablets debossed with 'H' on scored side and '114' on unscored side. They are supplied as follows:

Unit dose packages of 100 (10 x 10) NDC 60687-559-01

Methocarbamol tablets USP 750 mg are white to off white, capsule shaped, tablets debossed with 'H' on one side and '115' on other side. They are supplied as follows:

Unit dose packages of 100 (10 x 10) NDC 60687-568-01

**Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].**

**FOR YOUR PROTECTION:** Do not use if blister is torn or broken.

## **PACKAGING INFORMATION**

American Health Packaging unit dose blisters (see How Supplied section) contain drug product from Camber Pharmaceuticals, Inc. as follows:

(500 mg/ 100 UD) NDC 60687-559-01 packaged from NDC 31722-533

(750 mg/ 100 UD) NDC 60687-568-01 packaged from NDC 31722-534

Distributed by:

**American Health Packaging**

Columbus, OH 43217

**8455901/0320**

**Package/Label Display Panel - Carton - 500 mg**

NDC 60687-**559**-01

# Methocarbamol Tablets USP

**500 mg**

100 Tablets (10 x 10)

Rx Only



(01) 0 03 60687 559 01 8

NDC 60687-**559**-01

# Methocarbamol Tablets USP

**500 mg**

100 Tablets (10 x 10)

Rx Only

**Each Uncoated Tablet Contains:**

Methocarbamol USP .....500 mg

**Usual Dosage:** Two to four tablets four times daily. See full prescribing information.

**Store** at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

**FOR YOUR PROTECTION:** Do not use if blister is torn or broken.

The drug product contained in this package is from NDC # 31722-533, Camber Pharmaceuticals, Inc.

Distributed by: American Health Packaging, Columbus, Ohio 43217

Scan for current  
Prescribing Information →



755901  
0455901/0824

NDC 60687- **559**-01

**Methocarbamol**  
Tablets USP

**500 mg**

**100 Tablets (10 x 10)**

**Rx Only**

**Each Uncoated Tablet Contains:**

Methocarbamol USP .....500 mg

**Usual Dosage: Two to four tablets four times daily.** See full prescribing information.

**Store** at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

**FOR YOUR PROTECTION:** Do not use if blister is torn or broken.

The drug product contained in this package is from NDC # 31722-533, Camber Pharmaceuticals, Inc.

Distributed by: American Health Packaging, Columbus, Ohio 43217

755901  
0455901/0824

**Package/Label Display Panel - Blister - 500 mg**



Methocarbamol  
Tablet USP

**500 mg**

**Package/Label Display Panel - Carton - 750 mg**

NDC 60687-**568**-01

# Methocarbamol

Tablets USP

**750 mg**

100 Tablets (10 x 10)

Rx Only



(01) 0 03 60687 568 01 0

NDC 60687-**568**-01

# Methocarbamol

Tablets USP

**750 mg**

100 Tablets (10 x 10)

Rx Only

**Each Uncoated Tablet Contains:**

Methocarbamol USP ..... 750 mg

**Usual Dosage:** Two tablets three times daily. See full prescribing information.

**Store** at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

**FOR YOUR PROTECTION:** Do not use if blister is torn or broken.

The drug product contained in this package is from NDC # 31722-534, Camber Pharmaceuticals, Inc.

Distributed by: American Health Packaging, Columbus, Ohio 43217

Scan for current  
Prescribing Information →



756801  
0456801/0824

NDC 60687- **568**-01

**Methocarbamol**  
Tablets USP

**750 mg**

**100 Tablets (10 x 10)**

**Rx Only**

**Each Uncoated Tablet Contains:**

Methocarbamol USP .....750 mg

**Usual Dosage: Two tablets three times daily.** See full prescribing information.

**Store** at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

**Keep this and all drugs out of reach of children.**

**FOR YOUR PROTECTION:** Do not use if blister is torn or broken.

The drug product contained in this package is from NDC # 31722-534, Camber Pharmaceuticals, Inc.

Distributed by: American Health Packaging, Columbus, Ohio 43217

756801

0456801/0824

**Package/Label Display Panel - Blister - 750 mg**



Methocarbamol  
Tablet USP  
**750 mg**

<b>METHOCARBAMOL</b>			
methocarbamol tablet			
<b>Product Information</b>			
<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:60687-559(NDC:31722-533)
<b>Route of Administration</b>	ORAL		
<b>Active Ingredient/Active Moiety</b>			
	<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>
	METHOCARBAMOL (UNII: 125OD7737X) (METHOCARBAMOL - UNII:125OD7737X)	METHOCARBAMOL	500 mg
<b>Inactive Ingredients</b>			
	<b>Ingredient Name</b>	<b>Strength</b>	
	SODIUM LAURYL SULFATE (UNII: 368GB5141J)		


<b>SODIUM STARCH GLYCOLATE TYPE A POTATO</b> (UNII: 5856J3G2A2)	
<b>POVIDONE K90</b> (UNII: RDH86HJV5Z)	
<b>POLYETHYLENE GLYCOL, UNSPECIFIED</b> (UNII: 3WJQ0SDW1A)	
<b>SILICON DIOXIDE</b> (UNII: ETJ7Z6XBU4)	
<b>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</b> (UNII: RFW2ET671P)	
<b>STEARIC ACID</b> (UNII: 4ELV7Z65AP)	
<b>MAGNESIUM STEARATE</b> (UNII: 70097M6I30)	

### Product Characteristics

<b>Color</b>	white (White to Off-white)	<b>Score</b>	2 pieces
<b>Shape</b>	OVAL (Capsule shaped)	<b>Size</b>	15mm
<b>Flavor</b>		<b>Imprint Code</b>	114;H
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:60687-559-01	100 in 1 BOX, UNIT-DOSE	05/20/2020	
1	NDC:60687-559-11	1 in 1 BLISTER PACK; Type 0: Not a Combination Product		



## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA090200	05/20/2020	

## METHOCARBAMOL

methocarbamol tablet

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:60687-568(NDC:31722-534)
<b>Route of Administration</b>	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>METHOCARBAMOL</b> (UNII: 125OD7737X) (METHOCARBAMOL - UNII:125OD7737X)	METHOCARBAMOL	750 mg

## Inactive Ingredients

Ingredient Name	Strength
<b>SODIUM LAURYL SULFATE</b> (UNII: 368GB5141J)	
<b>SODIUM STARCH GLYCOLATE TYPE A POTATO</b> (UNII: 5856J3G2A2)	
<b>POVIDONE K90</b> (UNII: RDH86HJV5Z)	
<b>POLYETHYLENE GLYCOL, UNSPECIFIED</b> (UNII: 3WJQ0SDW1A)	
<b>MAGNESIUM STEARATE</b> (UNII: 70097M6I30)	
<b>SILICON DIOXIDE</b> (UNII: ETJ7Z6XBU4)	
<b>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</b> (UNII: RFW2ET671P)	
<b>STEARIC ACID</b> (UNII: 4ELV7Z65AP)	

## Product Characteristics

<b>Color</b>	white (White to Off-white)	<b>Score</b>	no score
<b>Shape</b>	OVAL (Capsule shaped)	<b>Size</b>	19mm
<b>Flavor</b>		<b>Imprint Code</b>	115;H
<b>Contains</b>			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:60687-568-01	100 in 1 BOX, UNIT-DOSE	05/20/2020	
1	NDC:60687-568-11	1 in 1 BLISTER PACK; Type 0: Not a Combination Product		



### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA090200	05/20/2020	

**Labeler** - American Health Packaging (929561009)

### Establishment

Name	Address	ID/FEI	Business Operations
American Health Packaging		929561009	repack(60687-559, 60687-568)

Revised: 9/2024

American Health Packaging